Saturday, December 21

Tag: CH:ROG

$19 Billion in a Week: AbbVie Makes Two Big Bets
9Dec By adminNo Comments
Money

$19 Billion in a Week: AbbVie Makes Two Big Bets

Early last week, AbbVie was on every healthcare investment banker’s list. But with two quick deal announcements under its belt in just six days, AbbVie may have transformed its pipeline in cancer and neurology and satiated its deal-making hunger.The Chicago-area company, best known for selling Botox and immune-disease drug Humira, announced on Thursday of last week it would pay $10.1 billion for biotech ImmunoGen. On Wednesday, it followed up with the acquisition of Cerevel Therapeutics for $8.7 billion.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
This $5 Billion Biotech Home Run Took Less Than a Year
25Oct By adminNo Comments
Money

This $5 Billion Biotech Home Run Took Less Than a Year

You can’t completely blame Pfizer’s executives, yet Roche’s $7 billion acquisition of a bowel-disease treatment that it owned until last year isn’t a great look.In a deal that now feels like a biotech version of “Moneyball,” Roivant announced it was selling an asset that only 11 months ago it got for free from Pfizer. (The Wall Street Journal had reported the talks back in July). Big pharma companies focused on the drug industry equivalent of free agent signings will often overlook one of their own hot prospects. In fact, Republican presidential candidate Vivek Ramaswamy founded Roivant on the idea that pharma’s trash can be another company’s treasure. But this one became an almost instant All-Star.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c...
Read More
This $5 Billion Biotech Home Run Took Less Than a Year
24Oct By adminNo Comments
World

This $5 Billion Biotech Home Run Took Less Than a Year

You can’t completely blame Pfizer’s executives, yet Roche’s $7 billion acquisition of a bowel-disease treatment that it owned until last year isn’t a great look.In a deal that now feels like a biotech version of “Moneyball,” Roivant announced it was selling an asset that only 11 months ago it got for free from Pfizer. (The Wall Street Journal had reported the talks back in July). Big pharma companies focused on the drug industry equivalent of free agent signings will often overlook one of their own hot prospects. In fact, Republican presidential candidate Vivek Ramaswamy founded Roivant on the idea that pharma’s trash can be another company’s treasure. But this one became an almost instant All-Star.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c...
Read More
Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Bln Deal
23Oct By adminNo Comments
World

Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Bln Deal

Updated Oct. 23, 2023 1:27 am ETRoche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion that will give it rights to a therapy for inflammatory bowel disease and potentially multiple other indications.The Swiss pharmaceutical giant said Monday that it will pay $7.1 billion upfront and make a near-term milestone payment of $150 million to acquire rights to develop and manufacture Telavant’s RVT-3101 drug candidate and commercialize it in the U.S. and in Japan.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Health Care Roundup: Market Talk
20Oct By adminNo Comments
World

Health Care Roundup: Market Talk

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0650 GMT – Roche Holding’s third-quarter sales update was underwhelming and consensus earnings estimates still look high for both this year and next, Deutsche Bank Research analyst Emmanuel Papadakis says in a research note. There are few reasons to believe the Swiss pharmaceutical giant’s stock underperformance will reverse anytime soon and clinical-trial updates due in the near term look unlikely to change that, DB Research says. “Whilst the market reaction was somewhat severe, that reflects a red tape and the reality is that the guidance update—or rather, lack thereof—was unhelpful and the story remains in a tough spot from which it appears there are f...
Read More